Rolling submissions of chemistry, manufacturing and controls information are playing a key role in accelerating regulatory reviews of COVID-19 vaccines and therapeutics to speeds never envisioned in the many acceleration initiatives of recent years.
A recent international regulatory panel discussion that pointed to several factors such as platform technologies and regulatory policies for pandemics that can play a role in safely rushing coronavirus vaccines to market